| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,089 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bonstein Sara |
Chief Financial Officer |
• – – |
2016-07-29 |
4 |
A |
$8.34 |
$2,035 |
D/D |
244 |
81,346 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• • – |
2016-06-30 |
4 |
D |
$8.09 |
$849 |
D/D |
(105) |
121,738 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• • – |
2016-06-30 |
4 |
A |
$8.09 |
$3,276 |
D/D |
405 |
121,843 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• • – |
2016-06-30 |
4 |
D |
$8.09 |
$4,458 |
D/D |
(551) |
309,770 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• • – |
2016-06-30 |
4 |
A |
$8.09 |
$14,174 |
D/D |
1,752 |
310,321 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-06-30 |
4 |
D |
$8.09 |
$582 |
D/D |
(72) |
125,676 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-06-30 |
4 |
A |
$8.09 |
$3,414 |
D/D |
422 |
125,748 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2016-06-30 |
4 |
D |
$8.09 |
$777 |
D/D |
(96) |
81,102 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2016-06-30 |
4 |
A |
$8.09 |
$3,058 |
D/D |
378 |
81,198 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2016-05-31 |
4 |
D |
$9.26 |
$2,482 |
D/D |
(268) |
308,569 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2016-05-31 |
4 |
A |
$9.26 |
$9,445 |
D/D |
1,020 |
308,837 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2016-05-31 |
4 |
D |
$9.26 |
$482 |
D/D |
(52) |
121,438 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2016-05-31 |
4 |
A |
$9.26 |
$2,185 |
D/D |
236 |
121,490 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-05-31 |
4 |
D |
$9.26 |
$343 |
D/D |
(37) |
125,326 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-05-31 |
4 |
A |
$9.26 |
$2,278 |
D/D |
246 |
125,363 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2016-05-31 |
4 |
D |
$9.26 |
$454 |
D/D |
(49) |
80,820 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2016-05-31 |
4 |
A |
$9.26 |
$2,037 |
D/D |
220 |
80,869 |
|
- |
|
| Mckearn Thomas J |
Director |
– • – |
2016-05-13 |
4 |
S |
$7.45 |
$30,545 |
D/D |
(4,100) |
82,120 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-05-02 |
4 |
S |
$7.51 |
$20,915 |
D/D |
(2,785) |
125,117 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• – – |
2016-05-02 |
4 |
S |
$7.51 |
$61,860 |
D/D |
(8,237) |
307,817 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2016-04-29 |
4 |
D |
$7.74 |
$457 |
D/D |
(59) |
80,649 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• – – |
2016-04-29 |
4 |
A |
$7.74 |
$2,036 |
D/D |
263 |
80,708 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-04-29 |
4 |
D |
$7.74 |
$952 |
D/D |
(123) |
127,902 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2016-04-29 |
4 |
A |
$7.74 |
$2,276 |
D/D |
294 |
128,025 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2016-04-29 |
4 |
D |
$7.74 |
$480 |
D/D |
(62) |
121,254 |
|
- |
|
465 Records found
|
|
Page 7 of 19 |
|
|
